Esther Cubo1, Jacques Doumbe2, Pablo Martinez-Martin3, Carmen Rodriguez-Blazquez4, Callixte Kuate2, Natividad Mariscal5, Irene Lopez6, Gustave Noubissi2, Yacouba Njankouo Mapoure2, Jean Louis Jon7, Salomon Mbahe2, Benjamin Tchaleu2, Maria-Jose Catalan8. 1. Neurology Department of Hospital Universitario Burgos, Spain. Electronic address: esthercubo@gmail.com. 2. Neurology Department Douala Laquintinie Hospital, Cameroon. 3. Research Unit, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain; National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain. 4. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain. 5. Neurology Department of Hospital Universitario Burgos, Spain. 6. Medical School Universidad Complutense, Madrid, Spain. 7. Psychiatry Department, Douala Laquintinie Hospital, Cameroon. 8. Neurology Department, Hospital Clínico San Carlos, Madrid, Spain.
Abstract
BACKGROUND: There are limited data in terms of the clinical profile of Parkinson's disease in sub-Saharan African patients. OBJECTIVE: To compare the clinical profile and access to standard antiparkinsonian therapies of a Cameroonian cohort of patients with an age, sex, and disease duration-matched Spanish cohort (Longitudinal Study of Parkinson's disease, ELEP). METHODS: Observational, cross-sectional design. Demographic data were collected and the following ELEP assessments were applied: Scales for Outcomes in Parkinson's disease (SCOPA) Motor, Autonomic, Cognition, Sleep and Psychosocial; Hoehn and Yahr staging; modified Parkinson Psychosis Rating Scale; Cumulative Illness Rating Scale-Geriatrics; Hospital Anxiety and Depression Scale; pain and fatigue visual analog scales; Zarit, and EuroQoL. RESULTS: 74 patients with idiopathic Parkinson's disease were included (37 from each country) with a mean age of 64.4±10.5 years old, 70.3% males, and mean disease duration of 5.6±5.9 years. Compared to the Spanish cohort, Cameroonians were intermittently treated, less frequently received dopaminergic agonists (p<0.001), had a trend for taking lower doses of levodopa (p=0.06), and were more frequently on anticholinergics (p<0.0005). Cameroonians were more severely impaired in terms of motor (Hoehn Yahr stage, p=0.03; SCOPA-Motor, p<0.001), cognitive status (p<0.001), anxiety and depression (p<0.001), psychosis (p=0.008), somnolence, fatigue and pain (p<0.001, respectively), caregiver burden (p<0.0001), and quality of life (p=0.002). Instead, autonomic, comorbidity, and nocturnal sleep problems were similarly found. CONCLUSIONS: Limited and intermittent access to dopaminergic drugs has a negative impact on motor symptoms, nonmotor symptoms and quality of life in patients with Parkinson's disease and their caregivers.
BACKGROUND: There are limited data in terms of the clinical profile of Parkinson's disease in sub-Saharan African patients. OBJECTIVE: To compare the clinical profile and access to standard antiparkinsonian therapies of a Cameroonian cohort of patients with an age, sex, and disease duration-matched Spanish cohort (Longitudinal Study of Parkinson's disease, ELEP). METHODS: Observational, cross-sectional design. Demographic data were collected and the following ELEP assessments were applied: Scales for Outcomes in Parkinson's disease (SCOPA) Motor, Autonomic, Cognition, Sleep and Psychosocial; Hoehn and Yahr staging; modified Parkinson Psychosis Rating Scale; Cumulative Illness Rating Scale-Geriatrics; Hospital Anxiety and Depression Scale; pain and fatigue visual analog scales; Zarit, and EuroQoL. RESULTS: 74 patients with idiopathic Parkinson's disease were included (37 from each country) with a mean age of 64.4±10.5 years old, 70.3% males, and mean disease duration of 5.6±5.9 years. Compared to the Spanish cohort, Cameroonians were intermittently treated, less frequently received dopaminergic agonists (p<0.001), had a trend for taking lower doses of levodopa (p=0.06), and were more frequently on anticholinergics (p<0.0005). Cameroonians were more severely impaired in terms of motor (Hoehn Yahr stage, p=0.03; SCOPA-Motor, p<0.001), cognitive status (p<0.001), anxiety and depression (p<0.001), psychosis (p=0.008), somnolence, fatigue and pain (p<0.001, respectively), caregiver burden (p<0.0001), and quality of life (p=0.002). Instead, autonomic, comorbidity, and nocturnal sleep problems were similarly found. CONCLUSIONS: Limited and intermittent access to dopaminergic drugs has a negative impact on motor symptoms, nonmotor symptoms and quality of life in patients with Parkinson's disease and their caregivers.
Authors: Njideka U Okubadejo; Oluwadamilola O Ojo; Kolawole W Wahab; Sani A Abubakar; Olugbo Y Obiabo; Fatai K Salawu; Ernest O Nwazor; Osigwe P Agabi; Olajumoke O Oshinaike Journal: Mov Disord Clin Pract Date: 2018-11-16
Authors: Ildefonso Rodríguez-Leyva; Ana Laura Calderón-Garcidueñas; María E Jiménez-Capdeville; Ana Arely Rentería-Palomo; Héctor Gerardo Hernandez-Rodriguez; Rodrigo Valdés-Rodríguez; Cornelia Fuentes-Ahumada; Bertha Torres-Álvarez; Julio Sepúlveda-Saavedra; Adolfo Soto-Domínguez; Martha E Santoyo; José Ildefonso Rodriguez-Moreno; Juan Pablo Castanedo-Cázares Journal: Ann Clin Transl Neurol Date: 2014-07-01 Impact factor: 4.511